Mélanie Da Silva

Title: Mélanie Da Silva: Innovator in Single-Domain Antibody Technology

Introduction

Mélanie Da Silva is a prominent inventor based in Saint-Macoux, France. She has made significant contributions to the field of biotechnology, particularly in the development of single-domain antibodies. Her innovative work has the potential to advance therapeutic applications and improve drug development processes.

Latest Patents

Mélanie Da Silva holds a patent for a single-domain antibody that binds to the G protein alpha. This invention comprises an amino acid sequence consisting of three CDR regions (CDR1 to CDR3) and four hinge regions (FR1 to FR4). The formula for this antibody is represented as FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (I). Notably, it has a dissociation constant (Kd), measured in FRET, of less than 100 nM. This patent highlights her expertise in antibody engineering and its applications in medical science.

Career Highlights

Throughout her career, Mélanie has worked with notable organizations such as Ciscio Bioassays and the Centre National De La Recherche Scientifique. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Mélanie has collaborated with several talented individuals, including Eric Jacques Christian Trinquet and Elodie Julie Dupuis. These partnerships have fostered a creative environment for innovation and have led to advancements in antibody technology.

Conclusion

Mélanie Da Silva is a trailblazer in the field of single-domain antibodies, with a patent that showcases her innovative spirit and dedication to scientific advancement. Her work continues to inspire future developments in biotechnology.